Amarillo Biosciences (OTCMKTS:AMAR) versus Anthem (NASDAQ:ANTX) Critical Analysis

Amarillo Biosciences (OTCMKTS:AMAR) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Profitability

This table compares Amarillo Biosciences and Anthem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarillo Biosciences	-41,453.98%	N/A	-574.29%
Anthem	N/A	-52.35%	-47.25%

Volatility & Risk

Amarillo Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Anthem has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Amarillo Biosciences and Anthem, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarillo Biosciences	0	0	0	0	0.00
Anthem	1	0	1	0	2.00

Anthem has a consensus price target of $9.00, indicating a potential upside of 80.72%. Given Anthem’s stronger consensus rating and higher possible upside, analysts plainly believe Anthem is more favorable than Amarillo Biosciences.

Earnings & Valuation

This table compares Amarillo Biosciences and Anthem”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A
Anthem	N/A	N/A	-$35.17 million	($1.10)	-4.53

Amarillo Biosciences has higher revenue and earnings than Anthem.

Insider and Institutional Ownership

90.5% of Anthem shares are owned by institutional investors. 34.4% of Amarillo Biosciences shares are owned by insiders. Comparatively, 20.8% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Anthem beats Amarillo Biosciences on 6 of the 11 factors compared between the two stocks.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

About Anthem

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.